Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CCNB2 | O95067 | 2/20 | 0.48 |
| ▸ | CCNE2 | O96020 | 2/20 | 0.48 |
| ▸ | CDK1 | P06493 | 2/20 | 0.48 |
| ▸ | CDK4 | P11802 | 2/20 | 0.48 |
| ▸ | CCNB1 | P14635 | 2/20 | 0.48 |
| ▸ | CCND1 | P24385 | 2/20 | 0.48 |
| ▸ | CCNE1 | P24864 | 2/20 | 0.48 |
| ▸ | CDK2 | P24941 | 2/20 | 0.48 |
| ▸ | CCNB3 | Q8WWL7 | 2/20 | 0.48 |
| ▸ | QPCT | Q16769 | 1/20 | 0.42 |
| ▸ | QPCTL | Q9NXS2 | 1/20 | 0.42 |
| ▸ | MTNR1A | P48039 | 9/20 | 0.41 |
| ▸ | MTNR1B | P49286 | 8/20 | 0.41 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.39 |
| ▸ | F13A1 | P00488 | 1/20 | 0.39 |
| ▸ | ACACB | O00763 | 4/20 | 0.39 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4228993 | 0.88 | CCNB2 (0.42) | CCNB2CCNE2CDK1CDK4CCNB1 | |
| SCHEMBL14396533 | 0.86 | CCNB2 (0.41) | CCNB2CCNE2CDK1CDK4CCNB1 | |
| SCHEMBL13853450 | 0.85 | CCNB2 (0.41) | CCNB2CCNE2CDK1CDK4CCNB1 | |
| SCHEMBL50579 | 0.81 | CCNE2 (0.46) | CCNE2CDK4CCND1CCNE1CDK2 | |
| SCHEMBL13616184 | 0.78 | CDK2 (0.48) | CCNB2CCNE2CDK1CDK4CCNB1 | |
| SCHEMBL48657 | 0.76 | L3MBTL1 (0.53) | CCNE2CCNE1CDK2SMN1; SMN2 | |
| SCHEMBL12441277 | 0.74 | CCNB2 (0.38) | CCNB2CCNE2CDK1CDK4CCNB1 | |
| SCHEMBL12255302 | 0.71 | CCNB2 (0.44) | CCNB2CCNE2CDK1CDK4CCNB1 | |
| SCHEMBL48713 | 0.71 | CCNB2 (0.37) | CCNB2CCNE2CDK1CDK4CCNB1 | |
| SCHEMBL2074090 | 0.71 | CCNB2 (0.37) | CCNB2CCNE2CDK1CDK4CCNB1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 17 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20130172349-A1 | INHIBITORS OF PHOSPHATIDYLINOSITOL 3-KINASE | NOVARTIS AG (CH) | 2013-07-04 | — | — | US | disclosed |
| US-20130172349-A1 | INHIBITORS OF PHOSPHATIDYLINOSITOL 3-KINASE | NOVARTIS AG (CH) | 2013-07-04 | — | — | US | disclosed |
| US-8404684-B2 | Inhibitors of phosphatidylinositol 3-kinase | NOVARTIS AG (CH) | 2013-03-26 | — | — | US | disclosed |
| US-8404684-B2 | Inhibitors of phosphatidylinositol 3-kinase | NOVARTIS AG (CH) | 2013-03-26 | — | — | US | disclosed |
| US-8202865-B2 | Oxadiazole derivatives | MERCK SERONO SA (CH) | 2012-06-19 | — | — | US | disclosed |
| US-8202865-B2 | Oxadiazole derivatives | MERCK SERONO SA (CH) | 2012-06-19 | — | — | US | disclosed |
| US-8129541-B2 | 5-phenylthiazole derivatives and use as PI3 kinase inhibitors | NOVARTIS AG (CH) | 2012-03-06 | — | — | US | disclosed |
| US-20110105535-A1 | INHIBITORS OF PHOSPHATIDYLINOSITOL 3-KINASE | NOVARTIS AG | 2011-05-05 | — | — | US | disclosed |
| US-20110105535-A1 | INHIBITORS OF PHOSPHATIDYLINOSITOL 3-KINASE | NOVARTIS AG | 2011-05-05 | — | — | US | disclosed |
| US-20100240658-A1 | Oxadiazole Derivatives | MERCK SERONO SA (CH) | 2010-09-23 | — | — | US | disclosed |
| US-20100240658-A1 | Oxadiazole Derivatives | MERCK SERONO SA (CH) | 2010-09-23 | — | — | US | disclosed |
| US-20100093690-A1 | 5-PHENYLTHIAZOLE DERIVATIVES AND USE AS PI3 KINASE INHIBITORS | BRUCE IAN | 2010-04-15 | — | — | US | disclosed |
| US-7687637-B2 | 5-phenylthiazole derivatives and use as Pi3 kinase inhibitors | NOVARTIS AG (CH) | 2010-03-30 | — | — | US | disclosed |
| EP-2157091-A1 | Inhibitors of phosphatidylinositol 3-kinase | Novartis AG (CH) | 2010-02-24 | — | — | EP | disclosed |
| WO-2009043889-A2 | OXADIAZOLE DERIVATIVES | MERCK SERONO S.A. (CH) | 2009-04-09 | — | — | WO | disclosed |
| US-20070032487-A1 | Inhibitors of phosphatidylinositol 3-kinase | NOVARTIS AG (CH) | 2007-02-08 | — | — | US | disclosed |
| US-20070032487-A1 | Inhibitors of phosphatidylinositol 3-kinase | NOVARTIS AG (CH) | 2007-02-08 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100093690-A1 | 5-PHENYLTHIAZOLE DERIVATIVES AND USE AS PI3 KINASE INHIBITORS | PIK3CA, PIK3R5, PIP5K1B | CCNB2 826/4885CCNE2 343/4885CDK1 69/4885 |
| US-20070032487-A1 | Inhibitors of phosphatidylinositol 3-kinase | PIK3CA, PIP4K2C, PIP4K2B | CCNB2 828/4885CCNE2 945/4885CDK1 123/4885 |
| US-20100240658-A1 | Oxadiazole Derivatives | OXA1L, RO60, NQO2 | CCNB2 168/4885CCNE2 114/4885CDK1 57/4885 |
| US-20110105535-A1 | INHIBITORS OF PHOSPHATIDYLINOSITOL 3-KINASE | PIK3CA, PIK3CD, PIP4K2C | CCNB2 865/4885CCNE2 967/4885CDK1 126/4885 |
| US-20130172349-A1 | INHIBITORS OF PHOSPHATIDYLINOSITOL 3-KINASE | PIK3CA, PIK3CD, PIP4K2C | CCNB2 865/4885CCNE2 967/4885CDK1 126/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.